ストックスクリーナーアプリを入手
6.79
0.30%
0.02
アフターアワーズ：
6.79
Emergent Biosolutions Inc (EBS) 最新ニュース
Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirt - The National Law Review
Precision Trading with Emergent Biosolutions Inc. (EBS) Risk Zones - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - prnewswire.com
Emergent BioSolutions Inc (ER4.DU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore
Emergent BioSolutions stock steady as investors weigh recent fundamentals - AD HOC NEWS
Emergent BioSolutions Inc. (EBS) Stock Analysis: Unpacking A 56.7% Potential Upside - DirectorsTalk Interviews
Emergent BioSolutions stock rises on Q2 beat and guidance - AD HOC NEWS
Emergent BioSolutions restarts Massachusetts manufacturing after $34.5M vaccine deal - bizjournals.com
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility - marketscreener.com
Emergent: The MCM Engine Runs, But Naloxone Is Breaking Down - Seeking Alpha
Emergent BioSolutions | 8-K: Current report - Moomoo
Emergent BioSolutions presents transformation update, Q2 results, $40M restructuring savings and revised FY26 guidance - TradingView
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Emergent Biosolutions Inc (EBS) Fundamental & Financial Data - Stocktwits
Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutio - The National Law Review
Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review
Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz
Emergent BioSolutions faces securities fraud pr... - Pluang
Gaithersburg's Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS - BioBuzz
Emergent BioSolutions repurchases $75 million in senior notes - investing.com
Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes, Reducing Debt to $364.7 Million - Quiver Quantitative
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes - marketscreener.com
A $68 million cash outlay retires $75 million in Emergent bond debt - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Reach Out - ACCESS Newswire
Emergent BioSolutions receives $24 million BARDA contract - grafa.com
2026-09-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Shareholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. Receives Contract Modification Valued At Approximately USD 24 Million From The Biomedical Advanced Research And Development Authority To Supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) - marketscreener.com
Emergent BioSolutions receives $24M anthrax vaccine contract By Investing.com - Investing.com Australia
EBS Looks 11.9% Overvalued on GF Value™ Amid Challenging Growth Outlook - GuruFocus
Emergent BioSolutions receives $24M anthrax vaccine contract - investing.com
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times
Emergent BioSolutions Awarded $24M CYFENDUS Contract | EBS Stock News - Stock Titan
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray - Bioscience Association Manitoba
EBS Looks 8.4% Overvalued on GF Value™ Amid Challenging Growth O - GuruFocus
Emergent BioSolutions wins Canada contract for overdose spray By Investing.com - Investing.com Nigeria
Emergent BioSolutions wins Canada contract for overdose spray - Investing.com Canada
Emergent BioSolutions Awarded Canadian Government Standing Offer for NARCAN Nasal Spray - Quiver Quantitative
Canadian public agencies can buy NARCAN for three years; the spray lasts four - Stock Titan
2026-08-30 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Investors to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. (EBS) Options Chain - finance.yahoo.com
Emergent Biosolutions Inc (EBS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Reach Out - ACCESS Newswire
Emergent (EBS) Shares: Gains 1.97% to Reach $5.18 in the Current Update; Level Watch: Traders Can Monitor the $4.92-$5.44 Range in the Available RecordMedian Line - careplusvn.com
EBS Reinstated by JP Morgan -- Current Rating Underweight - GuruFocus
2026-08-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS) - MarketBeat
EBS Looks 11.9% Undervalued on GF Value™ Despite Underweight Rat - GuruFocus
Emergent (EBS) Trading: Closes 1.66% Higher at $4.90 in the Current Update; Key Range - careplusvn.com
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Emergent (EBS) Price: Gains 4.94% to Reach $4.89 at the Close; Immediate View: the Near-Term Reference Band Stretches From $4.65 to $5.13 on the DayPrice Target - vinanet.vn
0.18%
0.69%
大文字化:
|
ボリューム (24 時間):